ArticleJournal of immunology (Baltimore, Md. : 1950)2010
Therapeutic targeting of Syk in autoimmune diabetes.
Article in Journal of immunology (Baltimore, Md. : 1950), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- Long-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.International journal of hematology · 2025Trial
- Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.European journal of clinical pharmacology · 2016Trial
- Syk inhibition limits autoimmunity and abnormal B cell phenotype and function in mice with B cell-specific TRAF3 deficiency.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- The small-molecule Syk inhibitor R788 inhibits hematopoiesis and worsens anemia in sickle cell disease mice.Blood vessels, thrombosis & hemostasis · 2026Article
- Targeting pattern recognition receptors for cancer therapy: Mechanisms and strategies.Acta pharmaceutica Sinica. B · 2025Review
- A genomics perspective of personalized prevention and management of obesity.Human genomics · 2024Review
- Pharmacological strategies for mitigating anti-TNF biologic immunogenicity in rheumatoid arthritis patients.Current opinion in pharmacology · 2023Review
- Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.Frontiers in immunology · 2023Article
- Application and prospect of targeting innate immune sensors in the treatment of autoimmune diseases.Cell & bioscience · 2022Review
- Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization.Scientific reports · 2022Article
- Spleen Tyrosine Kinase Mediates Microglial Activation in Mice With Diabetic Retinopathy.Translational vision science & technology · 2021Article
- Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.Blood advances · 2021Review
- Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies.Frontiers in cell and developmental biology · 2021Review
- Involvement of B Cells, Immunoglobulins, and Syk in the Pathogenesis of Abdominal Aortic Aneurysm.Journal of the American Heart Association · 2018Article
- Central role of PI3K-SYK interaction in fibrinogen-induced lamellipodia and filopodia formation in platelets.FEBS open bio · 2016Article
- Immune-inflammation gene signatures in endometriosis patients.Fertility and sterility · 2016Article
- Pancreas-protective effect of rituximab for acute-onset type 1 diabetes in the honeymoon period: a case report.Endocrinology, diabetes & metabolism case reports · 2016Article
- Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.Journal of the American Society of Nephrology : JASN · 2014Article
- Getting Syk: spleen tyrosine kinase as a therapeutic target.Trends in pharmacological sciences · 2014Review
- B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.Cancer cell · 2014Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
Abstract
In APCs, the protein tyrosine kinase Syk is required for signaling of several immunoreceptors, including the BCR and FcR. We show that conditional ablation of the syk gene in dendritic cells (DCs) abrogates FcgammaR-mediated cross priming of diabetogenic T cells in RIP-mOVA mice, a situation phenocopied in wild-type RIP-mOVA mice treated with the selective Syk inhibitor R788. In addition to blocking FcgammaR-mediated events, R788 also blocked BCR-mediated Ag presentation, thus broadly interrupting the humoral contributions to T cell-driven autoimmunity. Indeed, oral administration of R788 significantly delayed spontaneous diabetes onset in NOD mice and successfully delayed progression of early-established diabetes even when treatment was initiated after the development of glucose intolerance. At the DC level, R788 treatment was associated with reduced insulin-specific CD8 priming and decreased DC numbers. At the B cell level, R788 reduced total B cell numbers and total Ig concentrations. Interestingly, R788 increased the number of IL-10-producing B cells, thus inducing a tolerogenic B cell population with immunomodulatory activity. Taken together, we show by genetic and pharmacologic approaches that Syk in APCs is an attractive target in T cell-mediated autoimmune diseases such as type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.